Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
VARENICLINE (VARENICLINE TARTRATE)
PFIZER CANADA ULC
N07BA03
VARENICLINE
0.5MG
TABLET
VARENICLINE (VARENICLINE TARTRATE) 0.5MG
ORAL
11/56
Prescription
MISCELLANEOUS AUTONOMIC DRUGS
Active ingredient group (AIG) number: 0152190001; AHFS:
APPROVED
2014-11-20
_CHAMPIX (varenicline tartrate) - Product Monograph _ _Page 1 of 60 _ _ _ PRODUCT MONOGRAPH Pr CHAMPIX ® (varenicline tartrate tablets) 0.5 mg and 1.0 mg varenicline (as varenicline tartrate) Smoking-Cessation Aid Pfizer Canada Inc. 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 ® C.P. Pharmaceuticals International C.V. Pfizer Canada Inc., licensee © 2019 Pfizer Canada ULC Date of Revision: January 22, 2019 Submission Control No: 221214 _CHAMPIX (varenicline tartrate) - Product Monograph _ _Page 2 of 60 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................3 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................24 DOSAGE AND ADMINISTRATION ..............................................................................27 OVERDOSAGE ................................................................................................................29 ACTION AND CLINICAL PHARMACOLOGY ............................................................30 INDICATIONS AND CLINICAL USE ............................................................................32 STORAGE AND STABILITY ..........................................................................................40 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................40 PART II: SCIENTIFIC INFORMATION .......................................................... Belgenin tamamını okuyun